 Connection
Robert Hoyer to Humans
This is a "connection" page, showing publications Robert Hoyer has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.037 |
|
|
|
-
Hoyer RJ, Leung N, Witzig TE, Lacy MQ. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol. 2007 May; 82(5):409-13.
Score: 0.008
-
Hoyer RJ, Arora AS, Baron TH. Complications after traction removal of direct percutaneous endoscopic jejunostomy: three case reports. Gastrointest Endosc. 2005 Nov; 62(5):802-5.
Score: 0.007
-
Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, Samedi V, Bubak A, Greene C, Waxweiler T, Mehrotra S, Bhatia S, Gadwa J, Bickett T, Piper M, Fakhoury K, Liu A, Petit J, Bowles D, Thaker A, Atiyeh K, Goddard J, Hoyer R, Van Bokhoven A, Jordan K, Jimeno A, D'Alessandro A, Raben D, McDermott JD, Karam SD. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer. 2022 11; 3(11):1300-1317.
Score: 0.006
-
Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, Lowczak A, Aljumaily R, Rocha Lima CM, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621.
Score: 0.005
-
Hoyer RJ, Bratlie A, Schreuder GM, Hurley CK. Characterization of a novel HLA-B allele, B*0804, in a Norwegian family. Tissue Antigens. 1997 Sep; 50(3):308-10.
Score: 0.004
-
LeMarbre G, Schinstock C, Hoyer R, Krook J, Tefferi A. Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate. Leuk Res. 2007 Mar; 31(3):414-5.
Score: 0.002
-
Ellis JM, Hoyer RJ, Costello CN, Mshana RN, Quakyi IA, Mshana MN, Diaby B, Traore M, Johnson AH, Hurley CK. HLA-B allele frequencies in C?te d'Ivoire defined by direct DNA sequencing: identification of HLA-B*1405, B*4410, and B*5302. Tissue Antigens. 2001 Apr; 57(4):339-43.
Score: 0.001
-
Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000 Dec 01; 18(23):3964-73.
Score: 0.001
-
Lin YS, Hoyer RJ, Tang TF, Ng J, Hartzmann RJ, Hurley CK. Detection of four novel alleles: DRB1*1130, DRB1*13072, DRB1*1315 and DRB1*1331. Tissue Antigens. 2000 Jan; 55(1):92-6.
Score: 0.001
-
Hurley CK, Steiner N, Kosman C, Mitton W, Koester R, Bei M, Bush J, McCormack J, Hahn A, Henson V, Hoyer R, Wade JA, Hartzman RJ, Ng J. Novel HLA-A and HLA-B alleles. Tissue Antigens. 1998 Jul; 52(1):84-7.
Score: 0.001
-
Hurley CK, Steiner N, Hoyer RJ, Menchaca E, Mitton W, Simonis T, Hartzman RJ, Johnson AH, Ng J. Novel HLA-B alleles, B*8201, B*3515 and B*5106, add to the complexity of serologic identification of HLA types. Tissue Antigens. 1996 Mar; 47(3):179-87.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|